Purpose To investigate the effects of androgen-deprivation therapy (ADT) on MRI parameters and evaluate their associations with treatment response measures. Materials and methods The study included 30 men with histopathologically confirmed prostate cancer who underwent MRI before and after initiation of ADT. Thirty-four tumours were volumetrically assessed on DW-MRI (n=32) and DCE-MRI (n=18), along with regions of interest in benign prostatic tissue, to calculate apparent diffusion coefficient (ADC) and transfer constant (K trans ) values. Changes in MRI parameters and correlations with clinical parameters (change in prostatespecific antigen [PSA], treatment duration, PSA nadir) were assessed.
Introduction
In 2014, prostate cancer was expected to be the most common malignancy among men in the United States, for whom the lifetime risk of being diagnosed with the disease is approximately 15.3 % [1] . In patients with advanced or metastatic disease, androgen -deprivation therapy (ADT) has been shown to be of value for controlling both local and distant castrationsensitive tumours [2, 3] . ADT is also known to cause significant changes in the appearance of the prostate on MRI, including a diffuse decrease in signal intensity on T2-weighted images that can lead to overestimation of tumour presence after therapy and hinder the assessment of treatment response [4, 5] .
Multi-parametric MRI has shown great promise in tumour detection [6, 7] , assessment of tumour aggressiveness [8, 9] , and detection of local recurrence after surgery or radiation therapy [10] . However, few studies have investigated the effects of ADT on parameters in diffusion-weighted or dynamic contrast-enhanced MRI. As these techniques go beyond the depiction of anatomy, and aim to assess tumour characteristics such as increased cellularity and the presence of tumourinduced neovascularization, we hypothesized that they would allow for treatment monitoring in patients undergoing ADT if they proved to be associated with established clinical response markers, such as the decrease in serum levels of prostatespecific antigen (PSA) or PSA nadirs, which have been shown to influence outcomes [11] [12] [13] [14] .
Therefore, the purpose of this study was to investigate the effects of ADT on prostate volume and on diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI parameters, and to evaluate their associations with established measures of treatment response.
Materials and methods

Patients
This study was institutional review board (IRB)-approved and HIPAA-compliant. The IRB waived the requirement for informed consent. We performed a retrospective search of radiation-oncology databases for the years 2009 to 2012 for patients fulfilling the following criteria: (1) histopathologically confirmed (trans-rectal ultrasound-guided biopsy, TRUS) prostate cancer treated with ADT, (2) pre-therapeutic MRI examination featuring a DWI and/or DCE MRI sequence, and (3) follow-up MRI examination after the start of therapy but before radiotherapy (or any other therapy) began. This search identified 32 patients. Of those, one patient was excluded from analysis due to imaging artefacts, and another patient was excluded because of extensive post-biopsy changes and haemorrhage.
The baseline MRI was performed at a median 0.7 months before the start of ADT (range, 0.03-9.5 months), and the median time between the two MRI examinations was 4.0 months (range, 2.2-13.9 months). The median duration of ADT at the time of the second MRI was 98 days (range, 42-197 days) .
Clinical data (PSA values, clinical stage, and start, end, and type of ADT) were collected from the hospital's electronic medical records system. For PSA values, the measurements obtained closest to the dates of MRI examinations were selected (pre-ADT: median 1 day after first MRI, range, −52 to 202 days; after start of ADT: median 8 days after second MRI, range: −4 to 52 days). In addition, the lowest PSA value (nadir) during therapy and during the complete patient follow-up period were collected. PSA nadirs were reached after a median 145 (range, 29-327) days while the patient was still under therapy, and after a median 233 (range, 80-923) days when the follow-up period was included.
Androgen deprivation therapy consisted of standard treatment with an androgen receptor antagonist and/or a gonadotropin-releasing hormone analogue to achieve castrate levels of serum testosterone. After the second MRI, 9 of the 30 patients were treated with intensity-modulated radiation therapy (IMRT) to a dose level of either 81 Gy (n=2) or 86.4 Gy (n = 7). The remaining 21 patients were treated with brachytherapy, either as monotherapy with iodine-125 (I-125) implantation of 144 Gy (n=9) alone, or permanent seed implantation (100 Gy I-125) combined with IMRT at 50.4 Gy (n=12).
MRI examinations and image analysis
The final patient cohort comprised 30 patients. Of these, 34 index lesions were identified in 27 patients. No tumour could be delineated in the remaining three patients, such that only measurements in benign prostatic tissue were included in analysis. Thirty-two lesions in 25 patients were identified on DWI (DWI was not available for one patient, while tumour delineation was not possible on the ADC maps of another due to imaging artefacts); 18 lesions in 12 patients were identified on DCE MRI (high-temporal-resolution DCE was not available in 17 patients, and one patient was excluded from analysis due to belated start of contrast agent injection). Diffuse tumour infiltration did not allow for the evaluation of normal prostatic tissue in one patient, and prohibited measurements in the transition zone in another.
All MRI examinations were performed on MRI units manufactured by GE Healthcare (Waukesha, WI, USA) at a field strength of 3 Tesla (n=19) or 1.5 Tesla (n=11) at both baseline and follow-up examination, and featured the use of a pelvic phased-array coil with four channels and an endorectal coil. Of the 30 patients included in this retrospective analysis, 12 had pre-and post-therapeutic examinations at differing field strengths. The MRI protocol included T2-weighted sequences in axial, coronal, and sagittal orientations, as well as a DW sequence (TR=2000-9000, TE=69.2-116.5, matrix :96-192×96-256, slice thickness 3 mm, no intersection gap, field of view 14-30×14-24 cm) with b-values of 0 and 700 s/mm 2 (n=3) or 1,000 s/mm 2 (n=22), and a DCE T1-weighted sequence (TR=3.2-4.28, TE=0.93-1.52, matrix 256×128-160, mean slice thickness 5.3 mm, no intersection gap, field of view 24×24 cm, mean temporal resolution 10.3 s). ADC maps were generated on a voxel-wise basis for each patient using a monoexponential model.
To assess prostate volume, regions of interest were drawn on T2-weighted sequences by a radiologist with 10 years of experience in genitourinary MRI (OA), who was blinded to all clinical and histopathological data, using a commercial picture archiving and communications system (PACS) application (Centricity; GE Healthcare, Waukesha, WI, USA). Volumes were assessed for the whole prostate and the peripheral zone (PZ)/transition zone (TZ) individually.
In addition, a radiologist with a fellowship in genitourinary MRI (AMH), who was blinded to all clinical and histopathological data, evaluated all available sequences and identified up to three index lesions per patient that appeared highly likely to represent tumours on all sequences (focal hypointensity on T2-weighted imaging, diffusion restriction on DWI, and increased early contrast enhancement with consecutive washout on DCE MRI). Then, to volumetrically assess each lesion, a region of interest (ROI) encircling the tumour was drawn on each ADC map (i.e., slice) where it was visible, using ImageJ software (version 1.47 m, National Institutes of Health, Bethesda, MD, USA [15] ). The data from these ROIs were then analysed with in-house software written in MATLAB (The MathWorks, Inc., Natick, MA, USA), and median ADC values were generated on a per-lesion basis. The Dynamika software solution (Image Analysis Ltd., London, UK) was used in a similar manner to analyse the DCE MRI sequences: again, a region of interest was drawn around each lesion on each slice where the tumour was visible, and the transfer constant (K trans ) of the Tofts model [16] was calculated on a voxel-by-voxel basis. For this, a population-based arterial input function and reference T1 values (1,597 ms at 3 T, 1, 317 ms at 1.5 T) were used.
In addition, single ROIs were placed in normal-appearing peripheral and transition zone tissue (whenever not prohibited by diffuse tumour infiltration, see above) for each patient, and median ADC values and K trans values were calculated for the individual regions of interest.
Statistical analysis MRI parameters, PSA values, and volume measured at baseline and follow-up MRI were summarized as medians and ranges. For each patient, the relative change between the two examinations ([first MRI -second MRI]/ first MRI) was calculated separately for volume and for each available MRI parameter in PZ, TZ, and tumours. The relative change in PSA ([first PSA -second PSA]/first PSA) was also calculated for each patient. The Wilcoxon signed-rank test was used to assess the statistical significance of the changes in measurements. We then assessed correlations between the changes in PSA and volume, between the changes in PSA and tumour ADC and K trans , and between the duration of androgen deprivation therapy and the change in tumour ADC and K trans using the Spearman correlation coefficient among patients. A logistic regression and generalized estimating equation (GEE) method with an independent correlation matrix and robust standard errors were used to examine whether relative changes or post-therapeutic values of tumour ADC and K trans could be used to differentiate tumour from benign tissue in the peripheral or transition zone. The exact Wilcoxon rank-sum test was used to compare changes in tumour ADC and K trans between PSA nadir groups with measurable and non-measurable (<0.05 ng/ml) PSA levels. The p values were adjusted to control for false discovery rate (FDR) [17] in testing correlations and in the comparisons between PSA nadir groups.
A test with a p value of less than 0.05 was considered statistically significant. All statistical analyses were performed using the SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and R version 2.13 (The R Foundation for Statistical Computing) software packages.
Results
Patient and tumour characteristics
This study included 30 men (mean age, 69 years; range, 48-79 years), in which a total of 34 tumorous lesions were measured in 27 patients; 3 patients had two and 2 patients had three lesions measured. More detailed patient and tumour characteristics can be found in Table 1 . Table 2 , and their relative changes with therapy are summarized in Table 3 ( Fig. 1). Figure 2a /b demonstrates the changes between the two MRI examinations on DW and DCE MRI.
PSA values decreased by 94 % (p<0.001) with therapy, from a median of 6.98 ng/ml to a median of 0.42 ng/ml. Prostate volume also decreased significantly, by 33 % (9-58 %), from a median of 57 ml to a median of 39 ml (p<0.001), with the peripheral zone in particular demonstrating a larger decrease, of 44 %, compared with a 29 % decrease in transition zone volume.
Median tumour ADC values increased significantly, by 17 % (p<0.001), from 0.8 to 1.0×10 −3 mm 2 /s, whereas median ADC values for both PZ and TZ decreased significantly with therapy (p=0.001 and 0.022, respectively). The relative change in ADC values in tumour tissue was found to be significantly different from that in peripheral zone or transition zone tissue (adjusted p<0.001 for both comparisons). Also, post-therapeutic ADC values alone differed significantly between tumour and benign peripheral and transition zone tissue (adjusted p<0.001 for both comparisons).
Conversely, the median K trans value decreased significantly (p<0.001), by 56 %, in tumours, from 0.24 to 0.1 min −1 .
Median K trans values in benign peripheral (−48 %; p=0.077) and transition zone (−35 %; p=0.054) tissue also decreased, but the decreases did not reach statistical significance. The relative change in K trans did not differ significantly between tumour and benign tissue (adjusted p=0.14 for comparisons to both PZ and TZ tissue). There was also no significant difference in K trans values at follow-up MRI between tumour and benign tissue (adjusted p values of 0.149 and 0.337 for comparisons to PZ and TZ tissue, respectively).
Correlation of MRI findings with clinical variables
The relative changes in tumour ADC and PSA correlated significantly with each other (p=0.031, see Table 4 ). The relative change in prostate volume on MRI did not correlate with the relative change in PSA. Furthermore, no MRI parameters correlated significantly with the duration of treatment or the presence of a non-measurable PSA nadir during therapy (p≥0.39). However, descriptive analysis showed that tumour ADC values increased by 25 % during therapy in patients with a non-measurable PSA, whereas they increased by only 7 % in the group of patients with a measurable PSA (see Table 5 ).
Discussion
In our study, androgen deprivation therapy (ADT) caused a significant reduction in prostate volume, particularly in the peripheral zone. In addition, ADT caused ADC values to increase significantly in tumours while decreasing in benign prostatic tissue. The relative change in ADC values differed significantly between tumour and benign prostatic tissue, and post-therapeutic ADC values themselves also differed significantly between tumour and benign tissue. The transfer constant (K trans ) decreased in both tumour and benign tissue, but the decrease was only significant in tumours. Neither relative changes in K trans nor post-therapeutic K trans values differed significantly between tumour and benign tissue. The relative change of tumour ADC correlated significantly with the decrease in PSA, but there was no correlation between MRI parameters and duration of treatment or PSA nadirs.
ADT is common therapeutic approach for men with advanced prostate cancer, as it has proven to be of value for local and distant tumour control [2, 3] . However, while MRI is frequently used for prostate cancer detection, active surveillance, or response assessment after surgery or radiation therapy, its value in the assessment of the response to ADT remains unclear. This may be due to the known effect of ADT on the appearance of the prostate on T2-weighted MR images, which includes not only shrinking of the prostate but also a diffuse decrease of signal intensity, rendering tumour delineation difficult when relying on T2-weighted images alone [4, 5] . To date, the value of multi-parametric MRI in this setting has scarcely been investigated, and only a few studies have examined the effect of ADT on functional MRI parameters [18] [19] [20] . In accordance with previous studies, our study showed that ADT resulted in shrinking of the prostate as seen on MRI [4, 18, 21] . The peripheral zone in particular showed a marked (44 %) decrease in volume. These findings-as well as our finding that PSA fell by a median 94 % during ADT-align well with the fact that ADT is known to induce involution of glandular tissue in addition to stromal hypercellularity on histopathology [22] . Histopathological analyses indicate that ADT also has a distinct effect on tumour tissue in prostate cancer, resulting in a Bloss of glandular architecture, cytoplasmic clearing, nuclear pyknosis, cytoplasmic vacuolization and mucinous degeneration^ [22] . These histopathological changes should generally allow for increased diffusion after therapy, and therefore align very well with our finding of a significant increase in ADC values in prostate cancer with treatment. However, Barrett et al. [18] found no increased ADC values in a similar setting, though, like us, they saw a significant decrease of ADC values in benign prostatic tissue. This discrepancy may be due to the smaller number of patients in their study with DWI analysis (n = 18) and to differences between the DWI protocols (e.g., b-values) used in the two studies.
ADT is also known to cause devascularization in both tumorous and benign prostatic tissue [23] . This aligns with our finding of a significant decrease in the K trans in tumours, which has been found previously in patients undergoing ADT [18] [19] [20] . Although we also found decreased K trans in benign prostatic tissue, it was not statistically significant.
Our study expanded on previous reports by applying volumetric tumour assessment in place of single ROIbased analysis [19, 20] and by providing a more detailed assessment of the ability of multi-parametric MRI to monitor treatment response. While posttreatment ADC values differed significantly between tumour and benign tissue in the PZ and TZ, the great overlap of generated values, both in this and prior studies, renders tumour delineation difficult after therapy. However, because the relative change in ADC values differed significantly between tumour and benign tissue and also correlated with the relative change in PSA, it could be of use in monitoring treatment response. Since tumour ADC values increased with therapy, but those of benign tissue decreased, direct comparison between preand post-therapeutic MRI might help in delineating the tumour after treatment.
Neither the decrease in K trans nor the post-therapeutic K trans values themselves differed significantly between tumour and benign tissue, indicating that K trans might be of limited value in this clinical setting. Furthermore, the relative changes in ADC and K trans did not correlate with the duration of ADT. This may be because the changes in these MRI parameters occur early after the start of therapy, as ADT achieves serum castrate levels of testosterone after a few weeks [24] ; thus, a correlation might be found only if the second MRI were performed earlier than it was in this and prior studies.
PSA nadirs after the start of therapy have been shown to have prognostic value for men with prostate cancer [12] [13] [14] . Therefore, associations between PSA nadirs and MRI parameters could render MRI parameters particularly helpful for assessing response to ADT. However, MRI parameters did not differ significantly between patients with and without a measurable PSA nadir either during therapy or during the complete follow-up period. Reductions in ADC values did tend to be greater among patients with a non-measurable PSA during therapy, but this trend was not statistically significant.
Further studies are needed to investigate the value of multiparametric MRI for monitoring response to ADT. Ideally, these studies should build on our results and incorporate new approaches (e.g., intravoxel incoherent motion imaging), potentially leading to the identification of new imaging correlates for biological changes that occur in prostatic tissue during ADT.
We acknowledge certain limitations of our study. First, because of the limited number of patients, ) values before (pre) and after the start of (post) androgen deprivation therapy for each patient, stratified by peripheral zone (PZ), transition zone (TZ), and tumour particularly those with dynamic contrast-enhanced MRI measurements, it was not possible for us to further stratify our analysis, for example, by tumour Gleason score. Secondly, the use of databases from radiation-oncology for our initial search for patients may have introduced a selection bias towards patients with planned subsequent radiation therapy, and the fact that all lesions were assessed by a single reader may have inevitably led to bias with regard to which lesions were included for analysis. Additionally, even though we detected several statistically significant differences, there was significant overlap between, for example, changes in MRI parameters measured in prostate cancer and benign prostatic tissue, potentially limiting the value of our findings for routine clinical practice. Our results should therefore be regarded as preliminary, and future studies are needed to verify our findings in a larger patient cohort. Due to the retrospective nature of our study, we were not able to account for variations in the MRI protocols (e.g., with regard to field strength or b-values) or the treatment duration and the timing of the second MRI, which could have influenced our results. In particular, we could not account for differing field strengths between MRI examinations before and after the start of therapy in 12 of 30 patients, which could have influenced generated ADC values, or for the variability in time intervals between the beginning of ADT and MRI examinations. Finally, patients included in this study did have biopsy-proven prostate cancer, but whole-mount stepsection histopathological maps were not available for tumour localization, so the potential for errors in tumour assessment cannot be excluded. Therefore, our preliminary results require verification in a prospective trial with whole-mount histopathology or MRI-guided biopsy as standard of reference.
In conclusion, our study demonstrated that androgen deprivation therapy causes significant changes to prostate volume and to ADC and K trans values in both tumorous and benign prostatic tissue; of these, the change in tumour ADC values may be of use in the assessment of therapeutic response. However, future studies incorporating new imaging approaches are needed to establish multi-parametric MRI as a tool for monitoring response to androgen deprivation therapy. 
